Correlative Study Between Serum Matrix Metalloproteinase 9 Values and Neurologic Deficit in Acute, Primary, Supratentorial, Intracerebral Haemorrhage

Open access

Abstract

One of the essential characteristics of intracerebral haemorrhages (ICH) is the occurrence of brain oedema (BE). Matrix metalloproteinase-9 (MMP-9) belongs to the family of proteolytic enzymes connected with zinc, which in brain bleeding or a stroke can induce matrix proteolyse into the neurovascular unit, and increase the BE. The aim of the study was to determine the MMP-9 values in serum, and to assess the degree of correlation with neurological deficit in patients with acute, primary and supratentorial ICH.

Materials: The study was prospective and included 62 patients with ICH. The neurological deficit of the patients was evaluated by the National Institute Health Stroke Scale (NIHSS). Serum MMP-9 level was determined by enzyme-linked immune sorbent assay (ELISA). Patients were evaluated in three phases: 1st, 3rdand 7th day following the ICH.

Results: The mean age of the patients was 64.5 ± 9.4. Within the follow-up period, there was a significant rise of the NIHSS score in the first three days: 11.48 ± 3.7; 13.21 ± 3.78, and a significant rise of serum MMP-9, with greatest values in the third day: 134.7 ± 26.1 ng/ml (p = 0.000). There was a positive, significant correlation (r = 0.886, p = 0.000) between the serum MMP-9 concentration and the NIHSS score.

Conclusion: Our study showed that in the first three days of ICH, serum MMP-9 values were rising as well as the neurological deficit and the BE. Determination and evaluation of the MMP-9 in serum is an easy, non-invasive, routine laboratory procedure for the detection and follow-up of BE, and also determines further therapeutic strategy as well as prognosis in these patients.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1. Adams DR Victor M. Principles of Neurology. New York Mc Graw-Hill Inc 1993.

  • 2. Skidmore CT Andrefsky J. Spontaneous intracerebral hemorrhage: epidemiology patophysiology and medical menagement. Neurosurg Clin N Am. 2002; 13: 281–288.

  • 3. Bahemuka M Primary intracerebral hemorrhagy and heart weight: a clinicopathological case control re view of 218 patients. Stroke. 1987; 18: 531–536.

  • 4. Huang FP Xi G Keep RF et al. Brain edema after experimental intracerebral hemorrage; Role of hemglobin degradation products. J Neurosurg. 2002; 96: 287–293.

  • 5. Nagase H. Activation mechanisms of matrix metaloproteinases. Biol Chem. 1997; 378: 151–160.

  • 6. Rosenberg G Navratil M. Metalloproteinase inhbition blocks edema in intracerebral hemorrhage in the rat. Neurology. 1997; 48: 921–926.

  • 7. Lapchak P Chapman D Zivin J. Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke. Stroke. 2000; 31: 3034–40.

  • 8. Pfefferkorn T Rosenberg G. Closure of the blood– brain barrier by matrix metalloproteinase inhibition reduces rtPA-mediated mortality in cerebral ischemia with delayed reperfusion. Stroke. 2003; 34: 2025–30.

  • 9. Alvarez-Sabin J Delgado P Abilleira S Molina C Arenillas J Ribo M et al. Temporal profile of matrix metalloproteinases and their inhibitors after spontneous intracerebral hemorrhage: relationship to clincal and radiological outcome. Stroke. 2004; 35: 1316–22.

  • 10. Abilleira S Montaner J Molin C et al. Matrix metaloproteinase-9 contretation after spontaneous intracrebral hemorrhage. J Neurosurg. 2003; 99: 65–70.

  • 11. De Graba JT Hallenbeck MJ Pettigrew DK et al. Progresion in acute stroke: Value of the initial NIH stroke scale score on patients stratification in future trials. Stroke. 1999; 30: 1208–1212.

  • 12. Baird AE Dasche J Connor A et al. Comparision of retrospective and prospecive measurements of the national institutes of health stroke scale. Cerebrovasc Dis. 2000; 10: 80–81.

  • 14. Adams H. Handbook of cerebrovascular disease. New York: Dekker; 1996

  • 15. Abilleira S Montaner J Molin C et al. Matrix metalloproteinase-9 contretation after spontaneous intracerebral hemorrhage. J Neurosurg 2003; 99: 65–70.

  • 16. Leira R Davalos A Silva Y et al. Stroke Project Cerebrovascularis Diseases Group of Spanish Neu rological Society. Early neurological deterioration in intracerebral hemorrage: predictors and associated factors. Neurology. 2004; 63: 461–467.

  • 17. Tejima E Guo S Murata Y et al. Neuroprotective effects of overexpressing tissue inhibitor of metalloproteinase TIMP-1. J Neurotrauma. 2009; 26(11): 1935–1941.

  • 18. Mahajan SD Aalinkeel R Reynolds JL et al. Suppression of MMP-9 expression in brain micro-vascular endothelial cells (BMVEC) using a gold nanorod (GNR)-siRNA nanoplex. Immunol Invest. 2012; 41(4): 337–355.

Search
Journal information
Impact Factor
CiteScore 2017: 0.45

SCImago Journal Rank (SJR) 2018: 0.177

Cited By
Metrics
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 336 263 8
PDF Downloads 248 222 2